Safety and Efficacy of Expanded, Universal Donor Natural Killer Cells for Relapsed/Refractory AML
Phase 1/2
20
about 5 years
1–24
1 site in OH
What this study is about
This trial is testing the safety and effectiveness of a treatment using universal donor natural killer cells in people with relapsed or refractory acute myeloid leukemia (AML). The goal is to determine the best dose of this treatment.
Simplified from trial records by PatientMatch.
What you may be asked to do
- 1.Receive Universal Donor Natural Killer Cells
Participation Burden
What's physically and logistically required of participants.
Requires travel to a study site
How treatment is administered
Everyone gets the investigational treatment.
Extracted study details
Pulled from the trial record to show what is being tested and what the study is measuring.
Primary: Incidence and severity of adverse events
Secondary: CR rate after first cycle, Minimal Residual Disease (MRD) negative response rate by flow cytometry, Relapse free survival and overall survival
Oncology